September 27, 2019
Approximately 350,000 units of Tolcylen™ products have now been dispensed by over 2,200 physicians and clinics helping Tolcylen™ become the fastest growing product line in its category. Marlinz Pharma has received notice of allowance for it's 5th patent covering the Tolcylen™ product line.
August 28, 2019
Tolcylen™ has been approved for a multi-site, double-blinded, placebo-controlled drug study. The study is currently in the enrollment phase. This FDA registered study will measure mycological and clinical outcomes for intended and off-label uses. It will include approximately 120 patients from 6 clinical sites throughout the United States.
August 9, 2018
Marlinz Pharma has announced that they have reached a milestone of over 1300 physicians dispensing Tolcylen™ to their patients with over 185,000 units sold to date. Marlinz Pharma has been granted 2 patents covering the unique combination Tolcylen product lines.